Altimmune, Inc. Securities Fraud Investigation

Shamis & Gentile, P.A. reminds investors of the October 6, 2025 deadline to file a lead-plaintiff motion in the securities class action filed on behalf of investors who purchased or otherwise acquired Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) securities between August 10, 2023 and June 25, 2025 (the “Class Period”).

Investors who suffered losses in excess of $50,000 are encouraged to contact the firm now for more information on how to participate.

The class action complaint alleges that Altimmune and certain senior executives made materially false and misleading statements and/or concealed adverse facts about the Company’s lead drug candidate, pemvidutide, and the results of its IMPACT Phase 2b MASH trial.

According to the class action complaint, throughout the Class Period Altimmune repeatedly issued positive statements and guidance regarding the trial, highlighting its “first-in-class” potential and prospects for FDA approval, but failed to disclose that the trial was not on track to achieve statistical significance for the fibrosis-reduction primary endpoint. The Company allegedly inflated expectations by emphasizing MASH resolution and favorable trends while downplaying or omitting the high placebo response and the risk of missing a key efficacy measure. On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial that revealed the fibrosis reduction endpoint failed to reach statistical significance, attributing the miss in part to an unexpectedly high placebo response.

On this news, Altimmune’s stock price fell from $7.71 on June 25 to $3.61 on June 26, 2025, a decline of approximately 53% in a single day, wiping out a substantial portion of the Company’s market value.

If you purchased or otherwise acquired Altimmune (NASDAQ: ALT) securities between August 10, 2023 and June 25, 2025, you may move the Court no later than October 6, 2025 to request appointment as lead plaintiff in this action. Lead plaintiffs act on behalf of all other class members in directing the litigation. There is no cost or obligation to participate.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.